{
    "clinical_study": {
        "@rank": "26916", 
        "brief_summary": {
            "textblock": "This study is being done to determine the long-term safety and possible benefits of\n      transplanted Human Central Nervous System Stem Cells (HuCNS-SC) for patients with Geographic\n      Atrophy of Age-Related Macular Degeneration. This long-term follow-up study is limited to\n      those individuals who received a transplant of HuCNS-SC cells into one of their eyes as part\n      of the CL-N01-AMD study.  No additional study product will be given in this 4-year long-term\n      follow-up study."
        }, 
        "brief_title": "Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Age-Related Macular Degeneration", 
            "Geographic Atrophy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Atrophy", 
                "Geographic Atrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have completed Study CL-N01-AMD\n\n          -  Must be able to provide written informed consent prior to any study related\n             procedures\n\n          -  Agree to comply in good faith with all conditions of the study and to attend all\n             required study visits\n\n        Exclusion Criteria:\n\n          -  Inability to comply with study procedures or visits\n\n          -  Since enrolling in Study CL-N01-AMD, have entered, or are about to enter another\n             investigational study that, in the opinion of the Principal Investigator (PI), might\n             confound study interpretation.\n\n          -  Received off-study immunosuppressive agents in the lead-in study or are receiving any\n             immunosuppressive agents since completing the lead-in study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "51 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All subjects with age-related macular degeneration (AMD) with GA who received\n        transplantation of HuCNS-SC in Study CL-N01-AMD."
            }
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137915", 
            "org_study_id": "CL-N02-AMD"
        }, 
        "intervention": {
            "intervention_name": "Human Central Nervous System Stem Cells", 
            "intervention_type": "Biological", 
            "other_name": "HuCNS-SC"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "AMD", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75231"
                }, 
                "name": "Retina Foundation of the Southwest"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Long-Term Follow-up Study of the Phase I/II Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency and types of serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "At each of 11 visits over a period of 48 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137915"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Frequency and types of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "At each of 11 visits over a period of 48 months"
        }, 
        "source": "StemCells, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "StemCells, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}